Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($0.80), $0.10 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $1.21 million versus the consensus estimate of $2.66 million.

2025 Financial Guidance

Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund operations into mid-2027.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Morgan Stanley reports China property sales rise in 50 cities
• NVIDIA (NVDA) call put ratio 1.9 calls to 1 put with a focus on 5K contracts of October 160 puts